We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Tests Evaluated for G6PD Deficiency

By LabMedica International staff writers
Posted on 02 Sep 2013
Print article
Image: Fluorescent spot test method for glucose-6-phosphate dehydrogenase deficiency (Photo courtesy of Dr. Tundun Williams).
Image: Fluorescent spot test method for glucose-6-phosphate dehydrogenase deficiency (Photo courtesy of Dr. Tundun Williams).
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzyme defect, for which many different laboratory tests are available.

Most individuals with G6PD deficiency are asymptomatic, but a deficiency in this enzyme can result in acute haemolytic anaemia after exposure to oxidative agents, such as the consumption of fava beans or antimalarial drugs.

An international team of scientists led by those at Mahidol University (Bangkok, Thailand) investigated four G6PD activity detections methods including fluorescence spot (FS), methemoglobin reduction (MR), biochemical and cytochemical test. These methods accompanied with mutation analysis of blood samples were taken from 295 apparently healthy individuals aged 18 to 50 years. There were 67 males and 228 females all with unknown G6PD deficiency status.

The MR test was performed with minor modifications, and the FS was performed on the heparinized blood using a commercial kit (R&D Diagnostics; Cholargos, Greece). For the quantitative evaluation of G6PD activity, the G6PD kit from Biolabo SA (Maizy, France) was used. A cytochemical assay of cellular G6PD activity was performed with a minor modification and cells were analyzed for formazan presence by light microscopy.

DNA was extracted from G6PD-deficient blood samples by using Qiaquick Blood DNA extraction kit (Qiagen; Hilden, Germany). DNA sequencing was carried out initially in one direction in all exons, using either the forward or the reverse primer. Fluorescence-based cycle labeling of polymerase chain reaction (PCR) products was performed using the BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems; Foster City, CA, USA).

At least one G6PD mutation was identified in 42 of the 295 (14.2%) individuals and G6PD Viangchan was the most common and was detected in 36/42 (83.3%). The prevalence of G6PD deficiency was 6.1% by FS test and 7.1% by MR test. G6PD activity measured as international units per gram hemoglobin (IU/gHb) and was 11 ± 2.5 IU/gHb in nondeficient females, and 10.9 ± 0.6 IU/gHb in nondeficient males. The upper and lower limit cut-off points for partial deficiency in adults was 5.7 IU/gHb, 60% of the normal mean, and for severe deficiency it was 0.95 IU/gHb , 10% of the normal mean.

The authors concluded that using a cut-off number of negative cell of greater than 20% in the cytochemical assay to define G6PD deficiency, the prevalence of G6PD deficiency was closest to the molecular analysis of 12.9% G6PD-deficient compared to the others methods. Therefore, the cytochemical method is a significant predictor of this disease, while FS and MR test are recommended for the detection of severe G6PD deficiency in developing countries. G6PD deficiency is present in more than 400 million people worldwide. The study was published on August 21, 2013, in the Malaria Journal.

Related Links:
Mahidol University
Qiagen
Applied Biosystems


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Coagulation Analyzer
CS-2400

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.